We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Consort Medical Plc | CSRT | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1,010.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1,010.00 | 1,010.00 |
| Top Posts |
|---|
Posted at 18/11/2019 22:22 by cerrito I had some issues with my RNS feed so have just caught up with this and indeed I see that CSRT did not themselves issue a RNS this morning.As per my previous posts no surprise at all that this is subject to an offer, although I had been thinking in terms of private equity. Yes this is a rare enough type of company in an interesting niche that there is a chance of another offer so no real surprise that the current share price is higher than the offer price. Like many people here I am finding that almost a full time job to find homes for stock holdings being taken over-last week it was AMER. |
Posted at 21/8/2019 10:38 by cerrito Thanks for that BigBloke.As you say share price performance very disappointing and the current price the same as at May 18th 2007 when I made my first purchase at 749.77. I do not see the Chairman instigating a shake up of Management nor indeed do I see major shareholders like Invesco, Polar and Schroders agitating for change; as he has been in post since April if he was going to do it I feel he would have done it by now…although it is possible but to my mind very unlikely that the fire showed up very serious management failings.Just a gut feeling and I may be wrong and indeed will be interesting to see the voting figures at the AGM. All the strategic decisions you highlight would have been signed off by the Board and they are not blameless. Indeed I have just caught up with Carlo whose shares have been suspended because they cannot produce financials due to problems in their automotive division which makes one wonder why the CSRT ever got it into their head to make a tentative bid to buy the whole company; I did not give it much attention at the time as I had so few shares but very spooky-albeit that there has been a subsequent change of Chairman. You mention the sale of King=and of course they want to get back into the US;that said the reasons for the sale they gave at the time seemed logical to me. As per my 132 I see CSRT as a good target for private equity. As a matter of interest when did they can their R&D activities the previous time? |
Posted at 28/2/2019 21:22 by cerrito I see that RX Securities( of whom I have never heard but specialize in life science companies) have put out a note on CSRT following the Mylan announcement yesterday in which they maintain their buy recommendation and fair value of 1230p |
Posted at 11/10/2017 13:09 by cerrito A testament to the solidity of the CSRT shareholder base was that today's RNS with news of a 1%+ increase in the holding of Neptune was the first change in holdings RNS since January this year. |
Posted at 22/2/2016 10:33 by cerrito What caught my eye from this morning's announcement is that CSRT has 2k employees-never appreciated it was that big |
Posted at 07/1/2016 18:56 by martini Consort Medical plc (CSRT) PT Raised to GBX 1,150 at Investechxxp://zolmax.com/in |
Posted at 04/12/2015 18:56 by cerrito Gone through the interims.All rather complicated given trying to work out the impact of the Aesica acquisition and the fact that they did not have a results presentation webcast-I find these very useful. Overall I have the sense that we could have done with more info. Broadly speaking the kind of results we have come to expect- solid steady progress. Liked the cash flow statement with net cash from operating activities at £16 m well in excess of the £11m combined of investment and equity dividend outflows. Also the organic sales growth of both Bespak and Aesica. I was reminded of the importance of Europe to Aesica-ie European sales have gone up from £28m to £85m.Also Aesica had issues with profitability-its operating profit before special items was only £5m compared to Bespak's £11.5m and Aiseca's total assets at £286m dwarfed those of Bespak at £110m. Also Goodwill represents more than 25% of total assets and will be V interesting to read the footnotes on valuation of goodwill in the annual report. I am not planning to either buy or sell in the immediate future and my take is that for the next few months the share price will be on the 940/1020 range. PS Nicoventures seems to have gone V quiet PPS I see that following the results Investec have a buy with a tp at 1033 and Brewin Dolphin a hold-both of which to me are in the zone. I see that revenue projections for this FY are unchanged at £284.95m and earnings also unchanged at 50.85p PPPS I see they are talking about confidence in meeting board's expectations for the Full year and would be good if we knew what it is. |
Posted at 16/6/2015 16:40 by cerrito Had a look at the accounts and listened to the webcast.Putting on one side the increase in the IAS19 Pension Deficit and the £17m special charge from continuing operations, a lot of good news. Glenn emphasized in the webcast that he integration going on plan; bpk put three projects into their development programme where normally they would guide for one pa and debt s lower than forecast. Given the increase in shares probably not realistic to expect an increase in the dividend, and management said they wanted to decrease debt. I continue to feel very comfortable with my holding here and am not planning to buy or sell |
Posted at 29/1/2015 22:43 by cerrito Interested to read the announcement today. The way I read their comments today and indeed previously is that the plant for this has been built for 6 months and it seems unoccupied except for testing so quite a lot invested.Note that in the Annual/Interim Report they said to expect CE mark in H1 2015 . No emphasis on this product mentioned in the interims so perhaps do not see this as a key product, but also note they have invested £6m which for CSRT is a lot ie total investment in property plant and equipment was £7m in first half of this year. Cannot find any figure for total investment anticipated in Atlas and also today seems to be the first time we have been given a timeline. |
Posted at 02/8/2014 18:27 by cerrito Saw a comment in the FT on BAT's interim results saying the BAT CEO talking down the potential of e cigarettes.They mention vype which is on the market but my understanding is that CSRT are not involved in their manufacture. I went on the Nicoventures website and read the following quote Nicoventures' first licensed product will involve novel nicotine technology in a device being developed by Kind Consumer, a healthcare research and development company focused on inhalation technologies. The application for the licence for this product is currently being considered by the MHRA. The licence application for a second product, an e-cigarette developed by CN Creative, has also been submitted. unquote I guess it is the Kind Consumer project that CSRT are working on but every day that passes get less gungho on what Nicoventures may offer CSRT - |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
